氟奋乃静结构式
|
常用名 | 氟奋乃静 | 英文名 | Fluphenazine |
---|---|---|---|---|
CAS号 | 69-23-8 | 分子量 | 437.522 | |
密度 | 1.3±0.1 g/cm3 | 沸点 | 568.3±50.0 °C at 760 mmHg | |
分子式 | C22H26F3N3OS | 熔点 | 268-274℃ | |
MSDS | N/A | 闪点 | 297.5±30.1 °C | |
符号 |
GHS02, GHS06, GHS08 |
信号词 | Danger |
氟奋乃静用途氟奋乃静是一种口服有效的吩噻嗪类多巴胺受体拮抗剂。氟奋乃静用于精神分裂症的研究。氟奋乃静阻断神经元电压门控钠通道[1]。 |
中文名 | 氟奋乃静 |
---|---|
英文名 | fluphenazine |
中文别名 | 羟哌氟丙嗪 |
英文别名 | 更多 |
密度 | 1.3±0.1 g/cm3 |
---|---|
沸点 | 568.3±50.0 °C at 760 mmHg |
熔点 | 268-274℃ |
分子式 | C22H26F3N3OS |
分子量 | 437.522 |
闪点 | 297.5±30.1 °C |
精确质量 | 437.174866 |
PSA | 55.25000 |
LogP | 4.84 |
外观性状 | 白色结晶粉末 |
蒸汽压 | 0.0±1.6 mmHg at 25°C |
折射率 | 1.579 |
储存条件 | 本品应避光密闭保存。 |
分子结构 | 1、 摩尔折射率:114.30 2、 摩尔体积(cm3/mol):343.8 3、 等张比容(90.2K):885.9 4、 表面张力(dyne/cm):44.0 5、 极化率(10-24cm3):45.31 |
计算化学 | 1.疏水参数计算参考值(XlogP):无 2.氢键供体数量:1 3.氢键受体数量:8 4.可旋转化学键数量:6 5.互变异构体数量:无 6.拓扑分子极性表面积55.2 7.重原子数量:30 8.表面电荷:0 9.复杂度:544 10.同位素原子数量:0 11.确定原子立构中心数量:0 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:1 |
更多 | 1. 性状:暗褐色黏质油状物 2. 密度(g/mL,25/4℃):不确定 3. 相对蒸汽密度(g/mL,空气=1):不确定 4. 熔点(ºC):225~227 (分解)。 5. 沸点(ºC,常压):不确定 6. 沸点(ºC, 5.2kPa):不确定 7. 折射率:不确定 8. 闪点(ºC):不确定 9. 比旋光度(º):不确定 10. 自燃点或引燃温度(ºC):不确定 11. 蒸气压(kPa,25ºC):不确定 12. 饱和蒸气压(kPa,60ºC):不确定 13. 燃烧热(KJ/mol):不确定 14. 临界温度(ºC):不确定 15. 临界压力(KPa):不确定 16. 油水(辛醇/水)分配系数的对数值:不确定 17. 爆炸上限(%,V/V):不确定 18. 爆炸下限(%,V/V):不确定 19. 溶解性:易溶于水,略溶于甲醇,微溶于乙醇及氯仿,几乎不溶于苯和乙醚。有吸湿性 |
氟奋乃静毒理学数据: 急性毒性:大鼠腹腔LD50:100 mg/kg;大鼠皮下注射LD50:640 mg/kg;小鼠口经LD50:220 mg/kg;小鼠腹腔LD50:89 mg/kg; 小鼠静脉LD50:51 mg/kg; 繁殖:大鼠口经TDLo:62 mg/kgSEX/DURATION : female 9 day(s) pre-mating female 1-22 day(s) after conception; 大鼠口经TDLo:18 mg/kgSEX/DURATION : female 9 day(s) pre-mating; |
符号 |
GHS02, GHS06, GHS08 |
---|---|
信号词 | Danger |
危害声明 | H225-H301 + H311 + H331-H370 |
警示性声明 | P210-P260-P280-P301 + P310-P311 |
危害码 (欧洲) | F,T |
风险声明 (欧洲) | 11-23/24/25-39/23/24/25 |
安全声明 (欧洲) | 16-36/37-45 |
危险品运输编码 | UN1230 - class 3 - PG 2 - Methanol, solution |
~% 氟奋乃静 69-23-8 |
文献:Journal of Pharmaceutical Sciences, , vol. 67, # 2 p. 157 - 162 |
~% 氟奋乃静 69-23-8 |
文献:Journal of Pharmaceutical Sciences, , vol. 67, # 2 p. 157 - 162 |
~% 氟奋乃静 69-23-8 |
文献:Arzneimittel Forschung, , vol. 12, p. 937 - 942 |
~% 氟奋乃静 69-23-8 |
文献:Arzneimittel Forschung, , vol. 12, p. 937 - 942 |
由羟乙基哌嗪与溴代氯丙烷经烷基化再与2-三氟甲基吩噻嗪缩合成盐制得。用间三氟甲基苯胺经缩合、消除、环合等亦可制得。
Adherence challenges and long-acting injectable antipsychotic treatment in patients with schizophrenia.
J. Psychosoc. Nurs. Ment. Health Serv. 51(3) , 13-8, (2013) Medication nonadherence has been associated with persistence of psychotic symptoms, relapse, and hospitalization in patients with schizophrenia. Patients with untreated psychosis are significantly les... |
|
Latent inhibition in an insect: the role of aminergic signaling.
Learn. Mem. 19(12) , 593-7, (2012) Latent inhibition (LI) is a decrement in learning performance that results from the nonreinforced pre-exposure of the to-be-conditioned stimulus, in both vertebrates and invertebrates. In vertebrates,... |
|
[Copper intoxication decreases lifespan and induces neurologic alterations in Drosophila melanogaster].
Invest. Clin. 54(1) , 47-57, (2013) Wilson disease is a hereditary disorder caused by mutations of the ATP7B gene, which leads to intoxication with copper as a result of an unbalance of copper homeostasis. The clinical manifestations re... |
1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)- |
2-{4-[3-(2-trifluoromethyl-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-ethanol |
hiazine |
dapotum |
4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)-1-Piperazineethanol |
Sevinol |
Elinol |
Pacinol |
10-[3'-[4''-(b-Hydroxyethyl)-1''-piperazinyl]propyl]-3-trifluoromethylphenothiazine |
2-(Trifluoromethyl)-10-[3-[1-(b-hydroxyethyl)-4-piperazinyl]propyl]phenothiazine |
4-[3-[2-(Trifluoromethyl)-10H-phenothiazin-10-yl]propyl]-1-piperazineethanol |
4-[3-[2-(trifluoromethyl)phenothiazine-10-yl]propyl]-1-piperazineethanol |
S 94 |
2-(4-(3-(2-(Trifluoromethyl)-10H-phenothiazin-10-yl)propyl)piperazin-1-yl)ethanol |
Fluphenazine |
2-(4-{3-[2-(Trifluoromethyl)-10H-phenothiazin-10-yl]propyl}-1-piperazinyl)ethanol |
1-Piperazineethanol, 4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]- |
2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethanol |
1-(2-Hydroxyethyl)-4-[3-(trifluoromethyl-10-phenothiazinyl)propyl]piperazine |